Asset profile
Zinlirvimab
Monoclonal antibody
Evidence outlook · registrational
HIV: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-03.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 21 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zinlirvimab: this drug | Phase 3 | Monoclonal antibody | HIV envelope | ||
| Teropavimab | Phase 3 | Monoclonal antibody | HIV envelope | ||
| 10-1074 | Phase 2 | Monoclonal antibody | HIV envelope | ||
| 3BNC117 | Phase 2 | Monoclonal antibody | HIV envelope | ||
| Lotivibart | Phase 2 | Monoclonal antibody | HIV envelope | ||
| BNT351 | Phase 1 | Monoclonal antibody | HIV envelope | ||
| UVAX-1107 | Phase 1 | Vaccine | HIV envelope | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
October 2027 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.